{
  "success": true,
  "pagesUsed": [
    15,
    16,
    17,
    18,
    19
  ],
  "modelUsed": "gemini-3-flash-preview",
  "eligibility": {
    "eligibilityCriterionItems": [
      {
        "id": "eci_1",
        "name": "Informed Consent",
        "text": "Signed Informed Consent Form",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_2",
        "name": "Age Requirement",
        "text": "Age 18 years at time of signing Informed Consent Form",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_3",
        "name": "Compliance",
        "text": "Ability to comply with the study protocol, in the investigator's judgment",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_4",
        "name": "HCC Diagnosis",
        "text": "Locally advanced or metastatic and/or unresectable HCC with diagnosis confirmed by histology/cytology or clinically by American Association for the Study of Liver Diseases (AASLD) criteria in cirrhotic patients. Patients without cirrhosis require histological confirmation of diagnosis.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_5",
        "name": "Disease Status",
        "text": "Disease that is not amenable to curative surgical and/or locoregional therapies, or progressive disease after surgical and /or locoregional therapies",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_6",
        "name": "Prior Systemic Therapy",
        "text": "No prior systemic therapy (including systemic investigational agents) for HCC. Previous use of herbal therapies/traditional Chinese medicines with anti-cancer activity included in the label is allowed, provided that these medications are discontinued prior to randomization.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_7",
        "name": "Measurable Disease",
        "text": "At least 1 measurable (per RECIST 1.1) untreated lesion",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_8",
        "name": "Prior Local Therapy",
        "text": "Patients who received prior local therapy (e.g., radiofrequency ablation, percutaneous ethanol or acetic acid injection, cryoablation, high-intensity focused ultrasound, transarterial chemoembolization, transarterial embolization, etc.) are eligible provided the target lesion(s) have not been previously treated with local therapy or the target lesion(s) within the field of local therapy have subsequently progressed in accordance with RECIST v1.1",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_9",
        "name": "Tumor Tissue",
        "text": "Pretreatment tumor tissue sample (if available). If tumor tissue is available, a formalin-fixed, paraffin-embedded (FFPE) tumor specimen in a paraffin block (preferred) or approximately 1015 slides containing unstained, freshly cut, serial sections should be submitted along with an associated pathology report within 4 weeks of randomization. If FFPE specimens described above are not available, any type of specimens (including fine-needle aspiration, cell pellet specimens [e.g., from pleural effusion], and lavage samples) are also acceptable. This specimen should be accompanied by the associated pathology report. If tumor tissue is not available (e.g., depleted because of prior diagnostic testing), patients are still eligible.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_10",
        "name": "ECOG Performance Status",
        "text": "Eastern Cooperative Oncology Group Performance Status of 0 or 1 within 7 days prior to randomization",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_11",
        "name": "Child-Pugh Class",
        "text": "Child-Pugh Class A within 7 days prior to randomization",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_12",
        "name": "Hematologic and End-organ Function",
        "text": "Adequate hematologic and end-organ function, defined by the following laboratory test results, obtained within 7 days prior to randomization, unless otherwise specified: ANC 1.5 109/L (1500/L) without granulocyte colony-stimulating factor support; Lymphocyte count 0.5 109/L (500/L); Platelet count 75109/L (75,000/L) without transfusion; Hemoglobin 90 g/L (9 g/dL); AST, ALT, and alkaline phosphatase (ALP) 5upper limit of normal (ULN); Serum bilirubin 3ULN; Serum creatinine 1.5ULN or creatinine clearance 50 mL/min (calculated using the Cockcroft-Gault formula); Serum albumin 28 g/L (2.8 g/dL) without transfusion; For patients not receiving therapeutic anticoagulation: INR or aPTT 2ULN; Urine dipstick for proteinuria 2(within 7 days prior to initiation of study treatment).",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_13",
        "name": "Toxicity Resolution",
        "text": "Resolution of any acute, clinically significant treatment-related toxicity from prior therapy to Grade 1 prior to study entry, with the exception of alopecia",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_14",
        "name": "HIV Status",
        "text": "Negative HIV test at screening",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_15",
        "name": "Hepatitis Virology",
        "text": "Documented virology status of hepatitis, as confirmed by screening hepatitis B virus (HBV) and hepatitis C virus (HCV) serology test",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_16",
        "name": "Active HBV Management",
        "text": "For patients with active HBV: HBV DNA 500 IU/mL obtained within 28 days prior to initiation of study treatment, and Anti-HBV treatment (per local standard of care; e.g., entecavir) for a minimum of 14 days prior to study entry and willingness to continue treatment for the length of the study",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_17",
        "name": "Contraception - Women",
        "text": "For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods with a failure rate of 1% per year during the treatment period and for at least 5 months after the last dose of atezolizumab, 6 months after the last dose of bevacizumab, or 6 months after the last dose of sorafenib. Women must refrain from donating eggs during this same period.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_18",
        "name": "Contraception - Men",
        "text": "For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm, as defined below: With female partners of childbearing potential, men must remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of 1% per year during the treatment period and for 6 months after the last dose of bevacizumab or 3 months after the last dose of sorafenib. Men must refrain from donating sperm during this same period. With pregnant female partners, men must remain abstinent or use a condom during the treatment period and for 6 months after the last dose of bevacizumab or 3 months after the last dose of sorafenib to avoid exposing the embryo.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_19",
        "name": "China Enrollment Phase",
        "text": "For the extended China enrollment phase: Chinese ancestry and residence in Mainland China, Hong Kong, or Taiwan with enrollment at sites recognized by the China Center for Drug Evaluation",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_20",
        "name": "Leptomeningeal Disease",
        "text": "History of leptomeningeal disease",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_21",
        "name": "Autoimmune Disease",
        "text": "Active or history of autoimmune disease or immune deficiency, including, but not limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid antibody syndrome, Wegener granulomatosis, Sjögren syndrome, Guillain-Barré syndrome, or multiple sclerosis, with specific exceptions for hypothyroidism, Type 1 diabetes, and certain dermatologic conditions.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_22",
        "name": "Pulmonary Conditions",
        "text": "History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan. History of radiation pneumonitis in the radiation field (fibrosis) is permitted.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_23",
        "name": "Active Tuberculosis",
        "text": "Known active tuberculosis",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_24",
        "name": "Cardiovascular Disease",
        "text": "Significant cardiovascular disease (such as New York Heart Association Class II or greater cardiac disease, myocardial infarction, or cerebrovascular accident within 3 months prior to initiation of study treatment), unstable arrhythmia, or unstable angina",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_25",
        "name": "QT Interval",
        "text": "History of congenital long QT syndrome or corrected QT interval 500 ms (calculated with use of the Fridericia method) at screening",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_26",
        "name": "Electrolyte Disorder",
        "text": "History of uncorrectable electrolyte disorder affecting serum levels of potassium, calcium, or magnesium",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_27",
        "name": "Major Surgery",
        "text": "Major surgical procedure, other than for diagnosis, within 4 weeks prior to initiation of study treatment, or anticipation of need for a major surgical procedure during the study",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_28",
        "name": "Other Malignancy",
        "text": "History of malignancy other than HCC within 5 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death (e.g., 5-year overall survival [OS] rate 90%), such as adequately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, localized prostate cancer, ductal carcinoma in situ, or Stage I uterine cancer",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_29",
        "name": "Severe Infection",
        "text": "Severe infection within 4 weeks prior to initiation of study treatment, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia, or any active infection that, in the opinion of the investigator, could impact patient safety",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_30",
        "name": "Antibiotic Treatment",
        "text": "Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation of study treatment. Patients receiving prophylactic antibiotics are eligible.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_31",
        "name": "Transplantation",
        "text": "Prior allogeneic stem cell or solid organ transplantation",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_32",
        "name": "Other Contraindications",
        "text": "Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an investigational drug, may affect the interpretation of the results, or may render the patient at high risk from treatment complications",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_33",
        "name": "Live Vaccine",
        "text": "Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment, or anticipation of need for such a vaccine during atezolizumab treatment or within 5 months after the last dose of atezolizumab",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_34",
        "name": "Anaphylactic Reactions",
        "text": "History of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_35",
        "name": "Hypersensitivity",
        "text": "Known hypersensitivity to Chinese hamster ovary cell products or to any component of the atezolizumab or bevacizumab formulation",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_36",
        "name": "Pregnancy and Breastfeeding",
        "text": "Pregnant or breastfeeding, or intention of becoming pregnant during study treatment or within at least 5 months after the last dose of atezolizumab, 6 months after the last dose of bevacizumab, or 6 months after the last dose of sorafenib. Women of childbearing potential must have a negative serum pregnancy test result within 14 days prior to initiation of study treatment.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_37",
        "name": "Specific HCC Types",
        "text": "Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_38",
        "name": "Varices",
        "text": "Untreated or incompletely treated esophageal and/or gastric varices with bleeding or high risk for bleeding. Patients must undergo an EGD, and all size of varices must be assessed and treated per local standard of care prior to enrollment.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_39",
        "name": "Prior Bleeding Event",
        "text": "A prior bleeding event due to esophageal and/or gastric varices within 6 months prior to initiation of study treatment",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_40",
        "name": "Ascites",
        "text": "Moderate or severe ascites",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_41",
        "name": "Hepatic Encephalopathy",
        "text": "History of hepatic encephalopathy",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_42",
        "name": "HBV and HCV Coinfection",
        "text": "Coinfection of HBV and HCV. Patients with a history of HCV infection but who are negative for HCV RNA by PCR will be considered non-infected with HCV.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_43",
        "name": "CNS Metastases",
        "text": "Symptomatic, untreated, or actively progressing CNS metastases. Asymptomatic patients with treated CNS lesions are eligible under specific conditions (measurable disease outside CNS, no hemorrhage history, limited location, no interim progression, no recent radiotherapy/surgery, no ongoing corticosteroids).",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_44",
        "name": "Tumor-related Pain",
        "text": "Uncontrolled tumor-related pain. Patients requiring pain medication must be on a stable regimen at study entry.",
        "instanceType": "EligibilityCriterionItem"
      }
    ],
    "eligibilityCriteria": [
      {
        "id": "ec_1",
        "identifier": "1",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_1",
        "instanceType": "EligibilityCriterion",
        "name": "Informed Consent",
        "nextId": "ec_2"
      },
      {
        "id": "ec_2",
        "identifier": "2",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_2",
        "instanceType": "EligibilityCriterion",
        "name": "Age Requirement",
        "previousId": "ec_1",
        "nextId": "ec_3"
      },
      {
        "id": "ec_3",
        "identifier": "3",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_3",
        "instanceType": "EligibilityCriterion",
        "name": "Compliance",
        "previousId": "ec_2",
        "nextId": "ec_4"
      },
      {
        "id": "ec_4",
        "identifier": "4",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_4",
        "instanceType": "EligibilityCriterion",
        "name": "HCC Diagnosis",
        "previousId": "ec_3",
        "nextId": "ec_5"
      },
      {
        "id": "ec_5",
        "identifier": "5",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_5",
        "instanceType": "EligibilityCriterion",
        "name": "Disease Status",
        "previousId": "ec_4",
        "nextId": "ec_6"
      },
      {
        "id": "ec_6",
        "identifier": "6",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_6",
        "instanceType": "EligibilityCriterion",
        "name": "Prior Systemic Therapy",
        "previousId": "ec_5",
        "nextId": "ec_7"
      },
      {
        "id": "ec_7",
        "identifier": "7",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_7",
        "instanceType": "EligibilityCriterion",
        "name": "Measurable Disease",
        "previousId": "ec_6",
        "nextId": "ec_8"
      },
      {
        "id": "ec_8",
        "identifier": "8",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_8",
        "instanceType": "EligibilityCriterion",
        "name": "Prior Local Therapy",
        "previousId": "ec_7",
        "nextId": "ec_9"
      },
      {
        "id": "ec_9",
        "identifier": "9",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_9",
        "instanceType": "EligibilityCriterion",
        "name": "Tumor Tissue",
        "previousId": "ec_8",
        "nextId": "ec_10"
      },
      {
        "id": "ec_10",
        "identifier": "10",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_10",
        "instanceType": "EligibilityCriterion",
        "name": "ECOG Performance Status",
        "previousId": "ec_9",
        "nextId": "ec_11"
      },
      {
        "id": "ec_11",
        "identifier": "11",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_11",
        "instanceType": "EligibilityCriterion",
        "name": "Child-Pugh Class",
        "previousId": "ec_10",
        "nextId": "ec_12"
      },
      {
        "id": "ec_12",
        "identifier": "12",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_12",
        "instanceType": "EligibilityCriterion",
        "name": "Hematologic and End-organ Function",
        "previousId": "ec_11",
        "nextId": "ec_13"
      },
      {
        "id": "ec_13",
        "identifier": "13",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_13",
        "instanceType": "EligibilityCriterion",
        "name": "Toxicity Resolution",
        "previousId": "ec_12",
        "nextId": "ec_14"
      },
      {
        "id": "ec_14",
        "identifier": "14",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_14",
        "instanceType": "EligibilityCriterion",
        "name": "HIV Status",
        "previousId": "ec_13",
        "nextId": "ec_15"
      },
      {
        "id": "ec_15",
        "identifier": "15",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_15",
        "instanceType": "EligibilityCriterion",
        "name": "Hepatitis Virology",
        "previousId": "ec_14",
        "nextId": "ec_16"
      },
      {
        "id": "ec_16",
        "identifier": "16",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_16",
        "instanceType": "EligibilityCriterion",
        "name": "Active HBV Management",
        "previousId": "ec_15",
        "nextId": "ec_17"
      },
      {
        "id": "ec_17",
        "identifier": "17",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_17",
        "instanceType": "EligibilityCriterion",
        "name": "Contraception - Women",
        "previousId": "ec_16",
        "nextId": "ec_18"
      },
      {
        "id": "ec_18",
        "identifier": "18",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_18",
        "instanceType": "EligibilityCriterion",
        "name": "Contraception - Men",
        "previousId": "ec_17",
        "nextId": "ec_19"
      },
      {
        "id": "ec_19",
        "identifier": "19",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_19",
        "instanceType": "EligibilityCriterion",
        "name": "China Enrollment Phase",
        "previousId": "ec_18"
      },
      {
        "id": "ec_20",
        "identifier": "E1",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_20",
        "instanceType": "EligibilityCriterion",
        "name": "Leptomeningeal Disease",
        "nextId": "ec_21"
      },
      {
        "id": "ec_21",
        "identifier": "E2",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_21",
        "instanceType": "EligibilityCriterion",
        "name": "Autoimmune Disease",
        "previousId": "ec_20",
        "nextId": "ec_22"
      },
      {
        "id": "ec_22",
        "identifier": "E3",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_22",
        "instanceType": "EligibilityCriterion",
        "name": "Pulmonary Conditions",
        "previousId": "ec_21",
        "nextId": "ec_23"
      },
      {
        "id": "ec_23",
        "identifier": "E4",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_23",
        "instanceType": "EligibilityCriterion",
        "name": "Active Tuberculosis",
        "previousId": "ec_22",
        "nextId": "ec_24"
      },
      {
        "id": "ec_24",
        "identifier": "E5",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_24",
        "instanceType": "EligibilityCriterion",
        "name": "Cardiovascular Disease",
        "previousId": "ec_23",
        "nextId": "ec_25"
      },
      {
        "id": "ec_25",
        "identifier": "E6",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_25",
        "instanceType": "EligibilityCriterion",
        "name": "QT Interval",
        "previousId": "ec_24",
        "nextId": "ec_26"
      },
      {
        "id": "ec_26",
        "identifier": "E7",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_26",
        "instanceType": "EligibilityCriterion",
        "name": "Electrolyte Disorder",
        "previousId": "ec_25",
        "nextId": "ec_27"
      },
      {
        "id": "ec_27",
        "identifier": "E8",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_27",
        "instanceType": "EligibilityCriterion",
        "name": "Major Surgery",
        "previousId": "ec_26",
        "nextId": "ec_28"
      },
      {
        "id": "ec_28",
        "identifier": "E9",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_28",
        "instanceType": "EligibilityCriterion",
        "name": "Other Malignancy",
        "previousId": "ec_27",
        "nextId": "ec_29"
      },
      {
        "id": "ec_29",
        "identifier": "E10",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_29",
        "instanceType": "EligibilityCriterion",
        "name": "Severe Infection",
        "previousId": "ec_28",
        "nextId": "ec_30"
      },
      {
        "id": "ec_30",
        "identifier": "E11",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_30",
        "instanceType": "EligibilityCriterion",
        "name": "Antibiotic Treatment",
        "previousId": "ec_29",
        "nextId": "ec_31"
      },
      {
        "id": "ec_31",
        "identifier": "E12",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_31",
        "instanceType": "EligibilityCriterion",
        "name": "Transplantation",
        "previousId": "ec_30",
        "nextId": "ec_32"
      },
      {
        "id": "ec_32",
        "identifier": "E13",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_32",
        "instanceType": "EligibilityCriterion",
        "name": "Other Contraindications",
        "previousId": "ec_31",
        "nextId": "ec_33"
      },
      {
        "id": "ec_33",
        "identifier": "E14",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_33",
        "instanceType": "EligibilityCriterion",
        "name": "Live Vaccine",
        "previousId": "ec_32",
        "nextId": "ec_34"
      },
      {
        "id": "ec_34",
        "identifier": "E15",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_34",
        "instanceType": "EligibilityCriterion",
        "name": "Anaphylactic Reactions",
        "previousId": "ec_33",
        "nextId": "ec_35"
      },
      {
        "id": "ec_35",
        "identifier": "E16",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_35",
        "instanceType": "EligibilityCriterion",
        "name": "Hypersensitivity",
        "previousId": "ec_34",
        "nextId": "ec_36"
      },
      {
        "id": "ec_36",
        "identifier": "E17",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_36",
        "instanceType": "EligibilityCriterion",
        "name": "Pregnancy and Breastfeeding",
        "previousId": "ec_35",
        "nextId": "ec_37"
      },
      {
        "id": "ec_37",
        "identifier": "E18",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_37",
        "instanceType": "EligibilityCriterion",
        "name": "Specific HCC Types",
        "previousId": "ec_36",
        "nextId": "ec_38"
      },
      {
        "id": "ec_38",
        "identifier": "E19",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_38",
        "instanceType": "EligibilityCriterion",
        "name": "Varices",
        "previousId": "ec_37",
        "nextId": "ec_39"
      },
      {
        "id": "ec_39",
        "identifier": "E20",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_39",
        "instanceType": "EligibilityCriterion",
        "name": "Prior Bleeding Event",
        "previousId": "ec_38",
        "nextId": "ec_40"
      },
      {
        "id": "ec_40",
        "identifier": "E21",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_40",
        "instanceType": "EligibilityCriterion",
        "name": "Ascites",
        "previousId": "ec_39",
        "nextId": "ec_41"
      },
      {
        "id": "ec_41",
        "identifier": "E22",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_41",
        "instanceType": "EligibilityCriterion",
        "name": "Hepatic Encephalopathy",
        "previousId": "ec_40",
        "nextId": "ec_42"
      },
      {
        "id": "ec_42",
        "identifier": "E23",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_42",
        "instanceType": "EligibilityCriterion",
        "name": "HBV and HCV Coinfection",
        "previousId": "ec_41",
        "nextId": "ec_43"
      },
      {
        "id": "ec_43",
        "identifier": "E24",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_43",
        "instanceType": "EligibilityCriterion",
        "name": "CNS Metastases",
        "previousId": "ec_42",
        "nextId": "ec_44"
      },
      {
        "id": "ec_44",
        "identifier": "E25",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_44",
        "instanceType": "EligibilityCriterion",
        "name": "Tumor-related Pain",
        "previousId": "ec_43"
      }
    ],
    "summary": {
      "inclusionCount": 19,
      "exclusionCount": 25,
      "totalCount": 44
    },
    "population": {
      "id": "pop_1",
      "name": "Study Population",
      "includesHealthySubjects": false,
      "criterionIds": [
        "ec_1",
        "ec_2",
        "ec_3",
        "ec_4",
        "ec_5",
        "ec_6",
        "ec_7",
        "ec_8",
        "ec_9",
        "ec_10",
        "ec_11",
        "ec_12",
        "ec_13",
        "ec_14",
        "ec_15",
        "ec_16",
        "ec_17",
        "ec_18",
        "ec_19",
        "ec_20",
        "ec_21",
        "ec_22",
        "ec_23",
        "ec_24",
        "ec_25",
        "ec_26",
        "ec_27",
        "ec_28",
        "ec_29",
        "ec_30",
        "ec_31",
        "ec_32",
        "ec_33",
        "ec_34",
        "ec_35",
        "ec_36",
        "ec_37",
        "ec_38",
        "ec_39",
        "ec_40",
        "ec_41",
        "ec_42",
        "ec_43",
        "ec_44"
      ],
      "instanceType": "StudyDesignPopulation",
      "description": "Target population defined by eligibility criteria"
    }
  },
  "rawResponse": {
    "eligibilityCriteria": [
      {
        "id": "ec_1",
        "name": "Informed Consent",
        "identifier": "1",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_1",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_2",
        "name": "Age Requirement",
        "identifier": "2",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_2",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_3",
        "name": "Compliance",
        "identifier": "3",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_3",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_4",
        "name": "HCC Diagnosis",
        "identifier": "4",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_4",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_5",
        "name": "Disease Status",
        "identifier": "5",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_5",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_6",
        "name": "Prior Systemic Therapy",
        "identifier": "6",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_6",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_7",
        "name": "Measurable Disease",
        "identifier": "7",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_7",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_8",
        "name": "Prior Local Therapy",
        "identifier": "8",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_8",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_9",
        "name": "Tumor Tissue",
        "identifier": "9",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_9",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_10",
        "name": "ECOG Performance Status",
        "identifier": "10",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_10",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_11",
        "name": "Child-Pugh Class",
        "identifier": "11",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_11",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_12",
        "name": "Hematologic and End-organ Function",
        "identifier": "12",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_12",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_13",
        "name": "Toxicity Resolution",
        "identifier": "13",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_13",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_14",
        "name": "HIV Status",
        "identifier": "14",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_14",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_15",
        "name": "Hepatitis Virology",
        "identifier": "15",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_15",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_16",
        "name": "Active HBV Management",
        "identifier": "16",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_16",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_17",
        "name": "Contraception - Women",
        "identifier": "17",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_17",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_18",
        "name": "Contraception - Men",
        "identifier": "18",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_18",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_19",
        "name": "China Enrollment Phase",
        "identifier": "19",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_19",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_20",
        "name": "Leptomeningeal Disease",
        "identifier": "E1",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_20",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_21",
        "name": "Autoimmune Disease",
        "identifier": "E2",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_21",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_22",
        "name": "Pulmonary Conditions",
        "identifier": "E3",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_22",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_23",
        "name": "Active Tuberculosis",
        "identifier": "E4",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_23",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_24",
        "name": "Cardiovascular Disease",
        "identifier": "E5",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_24",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_25",
        "name": "QT Interval",
        "identifier": "E6",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_25",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_26",
        "name": "Electrolyte Disorder",
        "identifier": "E7",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_26",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_27",
        "name": "Major Surgery",
        "identifier": "E8",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_27",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_28",
        "name": "Other Malignancy",
        "identifier": "E9",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_28",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_29",
        "name": "Severe Infection",
        "identifier": "E10",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_29",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_30",
        "name": "Antibiotic Treatment",
        "identifier": "E11",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_30",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_31",
        "name": "Transplantation",
        "identifier": "E12",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_31",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_32",
        "name": "Other Contraindications",
        "identifier": "E13",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_32",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_33",
        "name": "Live Vaccine",
        "identifier": "E14",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_33",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_34",
        "name": "Anaphylactic Reactions",
        "identifier": "E15",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_34",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_35",
        "name": "Hypersensitivity",
        "identifier": "E16",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_35",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_36",
        "name": "Pregnancy and Breastfeeding",
        "identifier": "E17",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_36",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_37",
        "name": "Specific HCC Types",
        "identifier": "E18",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_37",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_38",
        "name": "Varices",
        "identifier": "E19",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_38",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_39",
        "name": "Prior Bleeding Event",
        "identifier": "E20",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_39",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_40",
        "name": "Ascites",
        "identifier": "E21",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_40",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_41",
        "name": "Hepatic Encephalopathy",
        "identifier": "E22",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_41",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_42",
        "name": "HBV and HCV Coinfection",
        "identifier": "E23",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_42",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_43",
        "name": "CNS Metastases",
        "identifier": "E24",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_43",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_44",
        "name": "Tumor-related Pain",
        "identifier": "E25",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_44",
        "instanceType": "EligibilityCriterion"
      }
    ],
    "eligibilityCriterionItems": [
      {
        "id": "eci_1",
        "name": "Informed Consent",
        "text": "Signed Informed Consent Form",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_2",
        "name": "Age Requirement",
        "text": "Age 18 years at time of signing Informed Consent Form",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_3",
        "name": "Compliance",
        "text": "Ability to comply with the study protocol, in the investigator's judgment",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_4",
        "name": "HCC Diagnosis",
        "text": "Locally advanced or metastatic and/or unresectable HCC with diagnosis confirmed by histology/cytology or clinically by American Association for the Study of Liver Diseases (AASLD) criteria in cirrhotic patients. Patients without cirrhosis require histological confirmation of diagnosis.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_5",
        "name": "Disease Status",
        "text": "Disease that is not amenable to curative surgical and/or locoregional therapies, or progressive disease after surgical and /or locoregional therapies",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_6",
        "name": "Prior Systemic Therapy",
        "text": "No prior systemic therapy (including systemic investigational agents) for HCC. Previous use of herbal therapies/traditional Chinese medicines with anti-cancer activity included in the label is allowed, provided that these medications are discontinued prior to randomization.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_7",
        "name": "Measurable Disease",
        "text": "At least 1 measurable (per RECIST 1.1) untreated lesion",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_8",
        "name": "Prior Local Therapy",
        "text": "Patients who received prior local therapy (e.g., radiofrequency ablation, percutaneous ethanol or acetic acid injection, cryoablation, high-intensity focused ultrasound, transarterial chemoembolization, transarterial embolization, etc.) are eligible provided the target lesion(s) have not been previously treated with local therapy or the target lesion(s) within the field of local therapy have subsequently progressed in accordance with RECIST v1.1",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_9",
        "name": "Tumor Tissue",
        "text": "Pretreatment tumor tissue sample (if available). If tumor tissue is available, a formalin-fixed, paraffin-embedded (FFPE) tumor specimen in a paraffin block (preferred) or approximately 1015 slides containing unstained, freshly cut, serial sections should be submitted along with an associated pathology report within 4 weeks of randomization. If FFPE specimens described above are not available, any type of specimens (including fine-needle aspiration, cell pellet specimens [e.g., from pleural effusion], and lavage samples) are also acceptable. This specimen should be accompanied by the associated pathology report. If tumor tissue is not available (e.g., depleted because of prior diagnostic testing), patients are still eligible.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_10",
        "name": "ECOG Performance Status",
        "text": "Eastern Cooperative Oncology Group Performance Status of 0 or 1 within 7 days prior to randomization",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_11",
        "name": "Child-Pugh Class",
        "text": "Child-Pugh Class A within 7 days prior to randomization",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_12",
        "name": "Hematologic and End-organ Function",
        "text": "Adequate hematologic and end-organ function, defined by the following laboratory test results, obtained within 7 days prior to randomization, unless otherwise specified: ANC 1.5 109/L (1500/L) without granulocyte colony-stimulating factor support; Lymphocyte count 0.5 109/L (500/L); Platelet count 75109/L (75,000/L) without transfusion; Hemoglobin 90 g/L (9 g/dL); AST, ALT, and alkaline phosphatase (ALP) 5upper limit of normal (ULN); Serum bilirubin 3ULN; Serum creatinine 1.5ULN or creatinine clearance 50 mL/min (calculated using the Cockcroft-Gault formula); Serum albumin 28 g/L (2.8 g/dL) without transfusion; For patients not receiving therapeutic anticoagulation: INR or aPTT 2ULN; Urine dipstick for proteinuria 2(within 7 days prior to initiation of study treatment).",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_13",
        "name": "Toxicity Resolution",
        "text": "Resolution of any acute, clinically significant treatment-related toxicity from prior therapy to Grade 1 prior to study entry, with the exception of alopecia",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_14",
        "name": "HIV Status",
        "text": "Negative HIV test at screening",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_15",
        "name": "Hepatitis Virology",
        "text": "Documented virology status of hepatitis, as confirmed by screening hepatitis B virus (HBV) and hepatitis C virus (HCV) serology test",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_16",
        "name": "Active HBV Management",
        "text": "For patients with active HBV: HBV DNA 500 IU/mL obtained within 28 days prior to initiation of study treatment, and Anti-HBV treatment (per local standard of care; e.g., entecavir) for a minimum of 14 days prior to study entry and willingness to continue treatment for the length of the study",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_17",
        "name": "Contraception - Women",
        "text": "For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods with a failure rate of 1% per year during the treatment period and for at least 5 months after the last dose of atezolizumab, 6 months after the last dose of bevacizumab, or 6 months after the last dose of sorafenib. Women must refrain from donating eggs during this same period.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_18",
        "name": "Contraception - Men",
        "text": "For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm, as defined below: With female partners of childbearing potential, men must remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of 1% per year during the treatment period and for 6 months after the last dose of bevacizumab or 3 months after the last dose of sorafenib. Men must refrain from donating sperm during this same period. With pregnant female partners, men must remain abstinent or use a condom during the treatment period and for 6 months after the last dose of bevacizumab or 3 months after the last dose of sorafenib to avoid exposing the embryo.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_19",
        "name": "China Enrollment Phase",
        "text": "For the extended China enrollment phase: Chinese ancestry and residence in Mainland China, Hong Kong, or Taiwan with enrollment at sites recognized by the China Center for Drug Evaluation",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_20",
        "name": "Leptomeningeal Disease",
        "text": "History of leptomeningeal disease",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_21",
        "name": "Autoimmune Disease",
        "text": "Active or history of autoimmune disease or immune deficiency, including, but not limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid antibody syndrome, Wegener granulomatosis, Sjögren syndrome, Guillain-Barré syndrome, or multiple sclerosis, with specific exceptions for hypothyroidism, Type 1 diabetes, and certain dermatologic conditions.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_22",
        "name": "Pulmonary Conditions",
        "text": "History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan. History of radiation pneumonitis in the radiation field (fibrosis) is permitted.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_23",
        "name": "Active Tuberculosis",
        "text": "Known active tuberculosis",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_24",
        "name": "Cardiovascular Disease",
        "text": "Significant cardiovascular disease (such as New York Heart Association Class II or greater cardiac disease, myocardial infarction, or cerebrovascular accident within 3 months prior to initiation of study treatment), unstable arrhythmia, or unstable angina",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_25",
        "name": "QT Interval",
        "text": "History of congenital long QT syndrome or corrected QT interval 500 ms (calculated with use of the Fridericia method) at screening",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_26",
        "name": "Electrolyte Disorder",
        "text": "History of uncorrectable electrolyte disorder affecting serum levels of potassium, calcium, or magnesium",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_27",
        "name": "Major Surgery",
        "text": "Major surgical procedure, other than for diagnosis, within 4 weeks prior to initiation of study treatment, or anticipation of need for a major surgical procedure during the study",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_28",
        "name": "Other Malignancy",
        "text": "History of malignancy other than HCC within 5 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death (e.g., 5-year overall survival [OS] rate 90%), such as adequately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, localized prostate cancer, ductal carcinoma in situ, or Stage I uterine cancer",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_29",
        "name": "Severe Infection",
        "text": "Severe infection within 4 weeks prior to initiation of study treatment, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia, or any active infection that, in the opinion of the investigator, could impact patient safety",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_30",
        "name": "Antibiotic Treatment",
        "text": "Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation of study treatment. Patients receiving prophylactic antibiotics are eligible.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_31",
        "name": "Transplantation",
        "text": "Prior allogeneic stem cell or solid organ transplantation",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_32",
        "name": "Other Contraindications",
        "text": "Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an investigational drug, may affect the interpretation of the results, or may render the patient at high risk from treatment complications",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_33",
        "name": "Live Vaccine",
        "text": "Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment, or anticipation of need for such a vaccine during atezolizumab treatment or within 5 months after the last dose of atezolizumab",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_34",
        "name": "Anaphylactic Reactions",
        "text": "History of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_35",
        "name": "Hypersensitivity",
        "text": "Known hypersensitivity to Chinese hamster ovary cell products or to any component of the atezolizumab or bevacizumab formulation",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_36",
        "name": "Pregnancy and Breastfeeding",
        "text": "Pregnant or breastfeeding, or intention of becoming pregnant during study treatment or within at least 5 months after the last dose of atezolizumab, 6 months after the last dose of bevacizumab, or 6 months after the last dose of sorafenib. Women of childbearing potential must have a negative serum pregnancy test result within 14 days prior to initiation of study treatment.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_37",
        "name": "Specific HCC Types",
        "text": "Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_38",
        "name": "Varices",
        "text": "Untreated or incompletely treated esophageal and/or gastric varices with bleeding or high risk for bleeding. Patients must undergo an EGD, and all size of varices must be assessed and treated per local standard of care prior to enrollment.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_39",
        "name": "Prior Bleeding Event",
        "text": "A prior bleeding event due to esophageal and/or gastric varices within 6 months prior to initiation of study treatment",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_40",
        "name": "Ascites",
        "text": "Moderate or severe ascites",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_41",
        "name": "Hepatic Encephalopathy",
        "text": "History of hepatic encephalopathy",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_42",
        "name": "HBV and HCV Coinfection",
        "text": "Coinfection of HBV and HCV. Patients with a history of HCV infection but who are negative for HCV RNA by PCR will be considered non-infected with HCV.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_43",
        "name": "CNS Metastases",
        "text": "Symptomatic, untreated, or actively progressing CNS metastases. Asymptomatic patients with treated CNS lesions are eligible under specific conditions (measurable disease outside CNS, no hemorrhage history, limited location, no interim progression, no recent radiotherapy/surgery, no ongoing corticosteroids).",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_44",
        "name": "Tumor-related Pain",
        "text": "Uncontrolled tumor-related pain. Patients requiring pain medication must be on a stable regimen at study entry.",
        "instanceType": "EligibilityCriterionItem"
      }
    ],
    "population": {
      "id": "pop_1",
      "name": "Study Population",
      "includesHealthySubjects": false,
      "plannedEnrollmentNumber": {
        "maxValue": 480,
        "instanceType": "Range"
      },
      "plannedMinimumAge": "P18Y",
      "plannedSex": [
        {
          "code": "Male",
          "codeSystem": "http://www.cdisc.org/USDM/sex",
          "decode": "Male"
        },
        {
          "code": "Female",
          "codeSystem": "http://www.cdisc.org/USDM/sex",
          "decode": "Female"
        }
      ],
      "criterionIds": [
        "ec_1",
        "ec_2",
        "ec_3",
        "ec_4",
        "ec_5",
        "ec_6",
        "ec_7",
        "ec_8",
        "ec_9",
        "ec_10",
        "ec_11",
        "ec_12",
        "ec_13",
        "ec_14",
        "ec_15",
        "ec_16",
        "ec_17",
        "ec_18",
        "ec_19",
        "ec_20",
        "ec_21",
        "ec_22",
        "ec_23",
        "ec_24",
        "ec_25",
        "ec_26",
        "ec_27",
        "ec_28",
        "ec_29",
        "ec_30",
        "ec_31",
        "ec_32",
        "ec_33",
        "ec_34",
        "ec_35",
        "ec_36",
        "ec_37",
        "ec_38",
        "ec_39",
        "ec_40",
        "ec_41",
        "ec_42",
        "ec_43",
        "ec_44"
      ],
      "instanceType": "StudyDesignPopulation"
    }
  }
}